Bevacizumab产品信息
名称:Anti-Bevacizumab Antibody
物种:Human/Mouse
属性:Antibody/Kits
标记:Biotin-labeled/Unconjugated
纯度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
![1.jpg 1.jpg](/SupplyImg/2024-05-06/6385060985832927238788628.jpg)
Bevacizumab分子背景
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
![通用.jpg 通用.jpg](/SupplyImg/2024-05-06/6385060986529059031750496.jpg)
关键字: Bevacizumab;Anti-Bevacizumab;Bevacizumab抗体;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。